InMed Pharmaceuticals (INM) FCF Margin (2021 - 2025)
InMed Pharmaceuticals' (INM) quarterly FCF Margin came in at 289.72% in Q4 2025, down 6465.0% year-on-year from 4.55% in Q4 2024, and down 101.86% quarter-over-quarter from 143.52% in Q3 2025.
InMed Pharmaceuticals (INM) FCF Margin (2021 - 2025) Analysis & Trends
InMed Pharmaceuticals' FCF Margin history runs 5 years deep, the most recent figure standing at 289.72% for Q4 2025.
- On a quarterly basis, FCF Margin fell 6465.0% year-over-year to 289.72% in Q4 2025; TTM through Dec 2025 was 164.69%, a 1348.0% decrease from a year earlier, with the FY2025 full-year figure at 157.14%, down 500.0% from the prior year.
- FCF Margin retreated to 289.72% in Q4 2025 per INM's latest filing, from 143.52% in the prior quarter.
- Across five years, FCF Margin topped out at 35.63% in Q2 2023 and bottomed at 1236.47% in Q4 2021.
- The 5-year median for FCF Margin is 166.17% (2024), against an average of 359.34%.
- Across the five-year window, FCF Margin soared 76382 bps in 2023 and sank 7620 bps in 2024, its largest moves.
- Year by year, FCF Margin stood at 1236.47% in 2021, then jumped by 53 bps to 577.52% in 2022, then jumped by 74 bps to 148.87% in 2023, then tumbled by 51 bps to 225.07% in 2024, then dropped by 29 bps to 289.72% in 2025.
- Per Business Quant, the three latest INM FCF Margin figures stand at 289.72% (Q4 2025), 143.52% (Q3 2025), and 136.31% (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -5.22% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 12.86% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -5.35% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 46.54% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 9.93% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 17.73% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.77% |
| 10 | InMed Pharmaceuticals | 307,858.50 | -4.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -289.72% |
| Sep 30, 2025 | -143.52% |
| Jun 30, 2025 | -136.31% |
| Mar 31, 2025 | -131.54% |
| Dec 31, 2024 | -225.07% |
| Sep 30, 2024 | -144.45% |
| Jun 30, 2024 | -80.21% |
| Mar 31, 2024 | -166.17% |
| Dec 31, 2023 | -148.87% |
| Sep 30, 2023 | -240.73% |
| Jun 30, 2023 | -35.63% |
| Mar 31, 2023 | -160.23% |
| Dec 31, 2022 | -577.52% |
| Sep 30, 2022 | -701.41% |
| Jun 30, 2022 | -799.46% |
| Mar 31, 2022 | -891.37% |
| Dec 31, 2021 | -1,236.47% |